ALTRINCHAM, England, July 3, 2025 /PRNewswire/ -- A new study is the first to examine the application of behavioural science in getting underused therapies...
STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate.
BEIJING, SHANGHAI and BOSTON, July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND)...
ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which...
GRAND JUNCTION, Colo., July 2, 2025 /PRNewswire/ -- Nuclear Care Partners proudly supports the Health Care for Energy Workers Act, a bipartisan bill introduced...
The sleep apnea market growth is driven by rising awareness, technological advancements, and demand for personalized care. Companies innovate therapies and solutions for better...
DENVER, July 02, 2025 (GLOBE NEWSWIRE) -- Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has received confirmation from The Nasdaq Stock Market that the Company has evidenced compliance with the minimum $2.5 million stockholders’ equity requirement and all other applicable criteria for continued listing on The Nasdaq Capital Market. Accordingly, the previously disclosed listing matter has been closed.
AUSTIN, Texas, July 02, 2025 (GLOBE NEWSWIRE) -- Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today announced the appointment of William B. (Billy) Cyr to its board of directors effective July 1, 2025.
OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1
MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC...